Enterprise Value

325.7M

Cash

260.4M

Avg Qtr Burn

-27.32M

Short % of Float

15.28%

Insider Ownership

5.02%

Institutional Own.

90.24%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
XPOVIO (Selinexor) (XPO1 inhibitor) Details
Multiple myeloma, Diffuse large B cell lymphoma, Cancer

Approved

Quarterly sales

Phase 3

Data readout

Phase 3

Initiation

Phase 2/3

Data readout

Eltanexor Details
Colorectal cancer , Prostate cancer, Multiple myeloma, Myelodysplastic syndrome

Phase 2

Data readout

XPOVIO (Selinexor) (XPO1 inhibitor) Details
Rare diseases, Liposarcoma, Cancer

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued